BYNDER
24.7.2024 15:01:34 CEST | Business Wire | Press release
Bynder, a global leader in enterprise digital asset management (DAM), has revealed how the accelerated adoption of the company’s AI-powered solutions and strategic DAM deployments have driven record growth in the first half of 2024.
More than 350 customers have adopted Bynder’s enhanced AI Search Experience since its launch nine months ago, and through the solution, more than 30 million images have been processed. Bynder, which currently has over 150 million active assets on its platform, also reported that in the first half of the year, it has seen a 20% year-on-year increase in the delivery of assets to connected systems. With assets delivered 113 billion times in the first half of the year, this shows that Bynder’s customers are continuing to leverage content as a strategic differentiator to deliver exceptional content experiences.
Bynder first integrated AI into its platform in 2016, demonstrating the company’s long-term commitment well before it became mainstream. Since then, Bynder has accelerated its efforts by acquiring an AI company and launching AI Search Experience, continually enhancing its AI capabilities and giving customers governance and control over how AI is used in their organizations and on their own terms.
Since the launch of Bynder’s AI Search Experience, many of Bynder's customers have adopted the solution, reinforcing the trend that AI is increasingly viewed as a strategic tool for marketers seeking to streamline content operations and improve customer experience. This trend validates Bynder's approach to AI, demonstrating the need to harness AI responsibly to deliver tangible benefits to its customers.
Bynder’s AI-powered DAM platform is pivotal in supporting go-to-market operations and the adoption of AI within content operations has driven the rapid uptake of Bynder’s AI Search Experience. This solution is customer-inspired and enables teams to maximize asset reuse, save resources, reduce time spent searching for assets, and automatically eliminate duplicates.
The benefits of the solution were evidenced at Bynder’s recent customer Spotlight Awards where brands such as Viator, Les Mills and Inspire Brands were recognized for their excellence in innovation, creating compelling value and return on investment when it comes to the implementation and use of Bynder DAM.
By leveraging AI-powered recommendations and filtering options, Inspire Brands was able to quickly locate and distribute relevant assets across its portfolio of sub-brands. This new level of findability has promoted content reuse within the organization and increased the value of the assets that the company invests in.
Cliff Crosbie, Head of AI Strategies at Bynder, said: “It’s great to see that our ongoing innovation and market leadership in AI has continued to drive growth in the first half of this year, along with our strategic DAM deployments which have both become invaluable solutions for our customers. The digital landscape continues to evolve faster than ever, so it’s our aim to implement AI responsibly to help drive scale and efficiency and we’re looking forward to bringing the next phase of our AI enhancements to market very soon.”
As a result of the company’s accelerated growth, Bynder has appointed Ann-Michèle Verheyden as its new Chief Legal Officer. Ann-Michèle brings extensive experience in SaaS, IP and privacy, supporting Bynder’s position and investment in AI where she will be building a robust compliance framework enabling businesses to navigate the complexities of AI-driven technology while mitigating risk.
Richard Heitmann also joins Bynder as its new Chief Marketing Officer. Richard brings a wealth of experience from high-growth startups like Aspera and enterprise software experience from IBM. Richard’s expertise will help drive further growth and bring Bynder’s platform innovations to the market.
Looking forward to the second half of the year, Bynder will host its inaugural customer event, Bynder Connect, in September in Amsterdam. The event will bring together industry leaders to share insights, launch new innovations, and celebrate successes with its customers.
For more information on Bynder’s AI-powered DAM, please visit: https://www.bynder.com/en/solutions/initiatives/ai-automation/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724434819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom